Actinogen Medical Ltd., of Sydney
Blocks activity of 11beta-HSD1
Mild Alzheimer's disease
Enrolled the final patient in the XanADu trial; 186-patient trial is comparing Xanamem to placebo in patients with mild dementia due to AD; results expected in the second quarter of 2019
Opthea Ltd., of Melbourne, Australia
Soluble form of VEGFR-3
Wet age-related macular degeneration
Last patient enrolled in the phase IIb trial, with total of 366; top-line data expected in the fourth quarter of 2019
Foresee Pharmaceuticals Co. Ltd., of Taipei, Taiwan
FP-001 (LMIS 25 mg)
Leuprolide mesylate injectable suspension
Advanced prostate cancer
All patients completed participation in the single-arm study; 144 patients enrolled to receive 2 consecutive injections for aggregated treatment duration of 6 months; top-line data expected in the first quarter of 2019
The date indicated refers to the BioWorld Clinical data table in which the news item can be found.
For more information about individual companies and/or products, see Cortellis.